By: IPP Bureau
Last updated : July 29, 2026 4:04 pm
As the company's domestic branded formulations business grows 14%, GLP-1 brand Sundae emerges as market leader by prescriptions
Eris Lifesciences Ltd. reported a 13 per cent year-on-year increase in consolidated revenue for the first quarter of FY27, with revenue from operations rising to Rs. 873 crore from Rs. 773 crore in the corresponding quarter last year.
The company posted a 14.5 per cent increase in Profit After Tax (PAT) to Rs. 143 crore, while EBITDA grew 7.1 per cent to Rs. 296 crore during the quarter ended June 30, 2026. The consolidated EBITDA margin stood at 33.9 per cent, compared with 35.8 per cent in Q1 FY26.
Gross profit increased 7.8 per cent year-on-year to Rs. 634 crore, while PAT margin improved marginally to 16.4 per cent from 16.2 per cent a year earlier.
The company's Domestic Branded Formulations (DBF) business recorded 14.2 per cent revenue growth during the quarter, supported by strong performance across its therapy portfolio. Seven of its ten therapeutic segments delivered double-digit growth, with the DBF business maintaining an EBITDA margin of 35 per cent.
Amit Bakshi, Chairman & Managing Director, Eris Lifesciences Ltd., said, "Our Domestic Branded Formulations business delivered a 14% YoY revenue growth in Q1 with 7 out of 10 therapies having delivered double digit growth rates. Our Insulins franchise continues to be an exciting story of market share gain, with significant headroom for growth from RHI, Glargine as well as Insulin Analogues.
“Our GLP-1 brand Sundae has taken off to a strong start with a rank of #1 by prescriptions and sales volume in Q1. Our consolidated revenue has grown by 13% YoY in Q1 with a PAT growth of 14.5%,” added Bakshi.
During the quarter, the company reported an operating cash flow to EBITDA conversion ratio of 77 per cent and incurred a capital expenditure of Rs. 88 crore, reflecting continued investments to support future growth.